OMICS Group is organizing 6thWorld Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit during August 17-19, 2015 Chicago, USA.
OMICS International Organises 300+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.
The Bioavailability Bioequivalence Research Center aims to become a regional center of excellence for assuring the safety and efficacy of generic pharmaceutical products for human use. It plays a key role in the drug development period for both new drug products and their generic equivalents. These studies are also important in the post approval period in the presence of certain manufacturing changes. Information in the overall set of data that ensure the availability of safe and effective medicines to patients and practitioners.
The global market for generic drugs was worth $81 billion in 2008, $84 billion in 2009, estimated to be $168.7 billion in 2014. Sales of U.S. generic drugs currently dominate the market with $54 billion for the 2014. Japan’s generic drugs market is expected to have the highest rate of growth among major markets at 12.2%, increasing from $5.4 billion in 2009 to $9.6 billion in 2014.
By 2016, it is expected that the value of the total global generics sector will have risen to $358 billion. The North American market is estimated to reach to reach nearly $107 billion in 2016 with an increase of 7.9% compound annual growth rate annual growth rate and Emerging market to reach nearly $115 billion.